Log In
Print
BCIQ
Print
Print this Print this
 

Fetzima, levomilnacipran (F2695)

  Manage Alerts
Collapse Summary General Information
Company Laboratoires Pierre Fabre S.A.
DescriptionSelective norepinephrine and serotonin reuptake inhibitor (NSRI)
Molecular Target
Mechanism of ActionNorepinephrine reuptake inhibitor; Selective serotonin reuptake inhibitor (SSRI)
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDepression
Indication DetailsTreat depression; Treat major depressive disorder (MDD)
Regulatory Designation U.S. - Undisclosed Review (Treat major depressive disorder (MDD))
Partner Allergan plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$75.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today